Abstract
Background Psychotherapy based on fear extinction is a mainstay of treatment for obsessive-compulsive disorder (OCD). The default mode network (DMN) is important to safety signal processing, fear extinction, and exposure-based therapies. The medial prefrontal cortex (mPFC) is an anchor of the DMN. Neuromodulation targeting the mPFC might augment therapeutic learning and thereby enhance response to exposure-based therapies.
Methods To characterize the effects of mPFC neuromodulation, 17 community volunteers completed resting-state fMRI scans before and after receiving 20 minutes of frontopolar multifocal transcranial direct current stimulation (tDCS). To examine the effects of tDCS on therapeutic learning, 24 patients with OCD were randomly assigned (double-blind, 50:50) to receive active or sham tDCS immediately before completing a two-day exposure and response prevention (ERP) challenge.
Results After tDCS, frontal pole functional connectivity with regions in the anterior insula and basal ganglia decreased, while connectivity in the middle and superior frontal gyri increased (ps<.001, corrected). Functional connectivity between DMN and salience network (SN) increased after tDCS (ps<.001). OCD patients who received active tDCS exhibited more rapid within- and between-trial therapeutic extinction learning (ps<.05) during the ERP challenge compared to those who received sham tDCS.
Conclusion tDCS targeting the mPFC may modulate SN and DMN functional connectivity and can accelerate therapeutic learning. Though limited by small samples, these promising findings motivate further exploration of the effects of tDCS on neural and behavioral targets associated with exposure-based treatments for OCD and for other anxiety and related disorders.
Competing Interest Statement
Dr. Adams, Dr. Cisler, Dr. Kelmendi, Ms. George, Mr. Kichuck, and Mr. Averill have no financial disclosures/conflicts to report. Dr. Anticevic consults and holds equity in Blackthorn Therapeutics. Dr. Abdallah has served as a consultant, speaker and/or on advisory boards for Genentech, Janssen, Psilocybin Labs, Lundbeck, Guidepoint and FSV7, and editor of Chronic Stress for Sage Publications, Inc.; He also filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (Aug 20, 2018). Dr. Pittenger serves as a consultant for Biohaven, Teva, Lundbeck, and Brainsway, receives royalties and/or honoraria from Oxford University Press and Elsevier, and has filed a patent on the use of NIRS neurofeedback in the treatment of anxiety, which is not relevant to the current work.
Clinical Trial
NCT03572543
Funding Statement
Dr. Adams and the reported studies were supported by the National Institute of Mental Health (NIMH; K23MH111977, T32MH062994, and L30MH111037). Study one was also supported, in part, by the Clinical Neurosciences Division of the National Center for PTSD and the Department of Veteran Affairs. Brain stimulation equipment was loaned by Starstim to support study pilots and was purchased using funds from the Detre Foundation (R13306). Study two was supported, in part, by an International Obsessive-Compulsive Disorder Foundation (IOCDF) Young Investigator Award and an American Psychiatric Association (APA) Psychiatric Fellowship Award (R12965). These studies were also supported by the State of Connecticut through its support of the Ribicoff Research Facilities at the Connecticut Mental Health Center. Dr. Anticevic is supported by the NIMH (R01MH108590). Dr. Abdallah is supported by the Beth K. and Stuart Yudofsky Chair in the Neuropsychiatry of Military Post Traumatic Stress Syndrome. Portions of these data were presented at annual conferences for the American College of Neuropsychopharmacology (ACNP) and Anxiety and Depression Association of America (ADAA). Dr. Pittenger is supported by the Taylor Family Foundation and the NIMH (R01MH116038 and K24MH121571). The views in this article are those of the authors, not of the State of Connecticut or of other funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All research was approved by the Yale School of Medicine Human Investigation Committee (HIC) / Institutional Review Board (IRB)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw study data are available upon request from the corresponding author.
